HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.107.046185v1 49/1/158    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldenberg, D. M. Articles by Chang, C.-H. Search for Related Content PubMed PubMed Citation Articles by Goldenberg, D. M. Articles by Chang, C.-H.

Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting

¹ Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey; ² IBC Pharmaceuticals, Inc., Morris Plains, New Jersey; and ³ Immunomedics, Inc., Morris Plains, New Jersey

Correspondence: For correspondence or reprints contact: David M. Goldenberg, ScD, MD, Garden State Cancer Center, CMMI, 520 Belleville Ave., Belleville, NJ 07109. E-mail: dmg.gscancer{at}att.net

The Dock-and-Lock (DNL) method, which makes bioactive molecules with multivalency and multifunctionality, is a new approach to develop targeting molecules for improved cancer imaging and therapy. It involves the use of a pair of distinct protein domains involved in the natural association between cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) and A-kinase anchoring proteins (AKAPs). The dimerization and docking domain found in the regulatory subunit of PKA and the anchoring domain (AD) of an interactive AKAP are each attached to a biologic entity, and the resulting derivatives, when combined, readily form a stably tethered complex of a defined composition that fully retains the functions of the individual constituents. The DNL method has generated several trivalent, bispecific, binding proteins, each consisting of 2 identical Fab fragments linked site-specifically to a different Fab fragment. For example, 2 identical Fabs reacting with carcinoembryonic antigen (CEA) are bound to a Fab reacting with a hapten peptide that bears a diagnostic or therapeutic radionuclide. Using a 2-step, pretargeting method that separates the bivalent anti-CEA antibody targeting of tumor from the delivery of the radioactive peptide that is captured by the second Fab of the tri-Fab construct, an improved method of cancer imaging and therapy has been developed and shows very sensitive and specific targeting of CEA-expressing tumors for either diagnostic imaging, such as with immunoSPECT and immunoPET, or radioimmunotherapy. Improved therapeutic efficacy is shown with pretargeting in a pancreatic cancer xenograft model given a tri-Fab to a pancreatic cancer MUC1 and the hapten peptide labeled with ⁹⁰Y.

Key Words: bispecific antibodies • cancer • PET • pretargeting • radioimmunodetection • radioimmunotherapy

Dr. Goldenberg is the recipient of the 2005 Paul C. Aebersold award of the SNM. He declares a financial interest in Immunomedics, Inc., and IBC Pharmaceuticals, Inc., as a stockholding officer of both corporations. Drs. Rossi, McBride, and Chang are employees and stockholders of Immunomedics and/or IBC Pharmaceuticals. Dr. Sharkey declares no financial interests.

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				D. V. Gold, D. M. Goldenberg, H. Karacay, E. A. Rossi, C.-H. Chang, T. M. Cardillo, W. J. McBride, and R. M. Sharkey A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma Cancer Res., June 15, 2008; 68(12): 4819 - 4826. [Abstract] [Full Text] [PDF]